FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2318371014> ?p ?o ?g. }

• W2318371014 endingPage "e134" @default.
• W2318371014 startingPage "e134" @default.
• W2318371014 abstract "The uridine nucleotide analogue sofosbuvir is a selective inhibitor of hepatitis C virus (HCV) NS5B polymerase. We assessed the safety and efficacy of sofosbuvir in combination with pegylated interferon alfa-2a (peginterferon) and ribavirin in non-cirrhotic treatment-naive, patients with HCV.For this open-label, randomised phase 2 trial, we recruited patients from 42 centres in the USA and Puerto Rico between March 23, 2011, and Sept 21, 2011. Patients were eligible for inclusion if they had chronic HCV infection (genotypes 1, 4, 5, or 6), were aged 18 years or older, and had not previously received treatment for HCV infection. Using a computer-generated randomisation sequence, we randomly assigned patients with HCV genotype-1 to one of three cohorts (A, B, and C; in a 1:2:3 ratio), with randomisation stratified by IL28B (CC vs non-CC allele) and HCV RNA (<800 000 IU/mL vs ≥800 000 IU/mL). Patients received sofosbuvir 400 mg plus peginterferon and ribavirin for 12 weeks (cohort A) or for 24 weeks (cohort B), or 12 weeks of sofosbuvir plus peginterferon and ribavirin followed by 12 weeks of either sofosbuvir monotherapy or sofosbuvir plus ribavirin (cohort C). We enrolled patients with all other eligible genotypes in cohort B. The primary efficacy endpoint was sustained virological response at post-treatment week 24 (SVR24) by intention-to-treat analysis. This trial is registered with ClinicalTrials.gov, number NCT01329978.We enrolled 316 patients with HCV genotype-1: 52 to cohort A, 109 to cohort B, and 155 to cohort C. We assigned 11 patients with HCV genotype-4 and five patients with genotype-6 to cohort B (we detected no patients with genotype 5). In patients with HCVgenotype-1, SVR24 was achieved by 46 patients (89%, 95% CI 77–96) in cohort A, 97 patients (89%, 82–94) in cohort B, and by 135 (87%, 81–92) in cohort C. We detected no difference in the proportion of patients achieving SVR24 in cohort A compared with cohort B (p=0·94), or in cohort C (p=0·78). Nine (82%) of 11 patients with genotype-4 and all five with genotype-6 achieved SVR24. Seven patients, all with genotype-1 infection, relapsed after completion of assigned treatment. The most common adverse events that led to the discontinuation of any study drug—anaemia and neutropenia—were associated with peginterferon and ribavirin treatment. Three (6%) patients in cohort A, 18 (14%) patients in cohort B, and three (2%) patients in cohort C discontinued treatment because of an adverse event.Our findings suggest that sofosbuvir is well tolerated and that there is no additional benefit of extending treatment beyond 12 weeks, but these finding will have to be substantiated in phase 3 trials. These results lend support to the further assessment of a 12 week sofosbuvir regimen in a broader population of patients with chronic HCV genotype-1 infection, including those with cirrhosis.Gilead Sciences." @default.
• W2318371014 created "2016-06-24" @default.
• W2318371014 creator A5034746829 @default.
• W2318371014 creator A5040000677 @default.
• W2318371014 creator A5073184804 @default.
• W2318371014 creator A5082783707 @default.
• W2318371014 creator A5086699641 @default.
• W2318371014 date "2014-03-01" @default.
• W2318371014 modified "2023-09-27" @default.
• W2318371014 title "PM357 Omega-3 fatty acid changes size and concentration of lipoproteins of Brazilian subjects included in Cardionutri study" @default.
• W2318371014 doi "https://doi.org/10.1016/j.gheart.2014.03.1705" @default.
• W2318371014 hasPublicationYear "2014" @default.
• W2318371014 type Work @default.
• W2318371014 sameAs 2318371014 @default.
• W2318371014 citedByCount "0" @default.
• W2318371014 crossrefType "journal-article" @default.
• W2318371014 hasAuthorship W2318371014A5034746829 @default.
• W2318371014 hasAuthorship W2318371014A5040000677 @default.
• W2318371014 hasAuthorship W2318371014A5073184804 @default.
• W2318371014 hasAuthorship W2318371014A5082783707 @default.
• W2318371014 hasAuthorship W2318371014A5086699641 @default.
• W2318371014 hasConcept C126322002 @default.
• W2318371014 hasConcept C159047783 @default.
• W2318371014 hasConcept C203092338 @default.
• W2318371014 hasConcept C2522874641 @default.
• W2318371014 hasConcept C2776408679 @default.
• W2318371014 hasConcept C2776455275 @default.
• W2318371014 hasConcept C2778390639 @default.
• W2318371014 hasConcept C2780040827 @default.
• W2318371014 hasConcept C535046627 @default.
• W2318371014 hasConcept C71924100 @default.
• W2318371014 hasConcept C72563966 @default.
• W2318371014 hasConcept C90924648 @default.
• W2318371014 hasConceptScore W2318371014C126322002 @default.
• W2318371014 hasConceptScore W2318371014C159047783 @default.
• W2318371014 hasConceptScore W2318371014C203092338 @default.
• W2318371014 hasConceptScore W2318371014C2522874641 @default.
• W2318371014 hasConceptScore W2318371014C2776408679 @default.
• W2318371014 hasConceptScore W2318371014C2776455275 @default.
• W2318371014 hasConceptScore W2318371014C2778390639 @default.
• W2318371014 hasConceptScore W2318371014C2780040827 @default.
• W2318371014 hasConceptScore W2318371014C535046627 @default.
• W2318371014 hasConceptScore W2318371014C71924100 @default.
• W2318371014 hasConceptScore W2318371014C72563966 @default.
• W2318371014 hasConceptScore W2318371014C90924648 @default.
• W2318371014 hasIssue "1" @default.
• W2318371014 hasLocation W23183710141 @default.
• W2318371014 hasOpenAccess W2318371014 @default.
• W2318371014 hasPrimaryLocation W23183710141 @default.
• W2318371014 hasRelatedWork W2114705120 @default.
• W2318371014 hasRelatedWork W2258641314 @default.
• W2318371014 hasRelatedWork W2420993274 @default.
• W2318371014 hasRelatedWork W2537134414 @default.
• W2318371014 hasRelatedWork W2585250246 @default.
• W2318371014 hasRelatedWork W2806466804 @default.
• W2318371014 hasRelatedWork W2894630148 @default.
• W2318371014 hasRelatedWork W3036186533 @default.
• W2318371014 hasRelatedWork W3214363948 @default.
• W2318371014 hasRelatedWork W4236806343 @default.
• W2318371014 hasVolume "9" @default.
• W2318371014 isParatext "false" @default.
• W2318371014 isRetracted "false" @default.
• W2318371014 magId "2318371014" @default.
• W2318371014 workType "article" @default.